Results 61 to 70 of about 344,100 (302)
Prevention and treatment of ventilator-associated pneumonia in COVID-19
Frontiers in Pharmacology, 2022 Ventilator-associated pneumonia (VAP) is the most common acquired infection in the intensive care unit. Recent studies showed that the critical COVID-19 patients with invasive mechanical ventilation have a high risk of developing VAP, which result in a ...
Jiayi Deng +4 more
doaj +1 more source
Potential therapeutic drug candidates against SARS-CoV-2 (COVID‐19) through molecular docking: A review [PDF]
Health Science Monitor, 2022 The severe acute respiratory syndrome coronavirus 2 (known as COVID-19), initially appeared in the Wuhan city of China in December 2019, has become a current medical issue around the world.
Aynaz Nourani +2 more
doaj
Drug Repurposing in the Treatment of COVID-19
Bezmialem Science, 2020 The use of drugs that have been previously defined for certain indications in new indications is defined as the repurposing/repositioning of the drug. The requirement of all clinical research steps that starts from healthy volunteers, due to the slowness of new drug discovery, longer time to reach the market, and high cost to develop a new drug, make ...
Mehmet SOYLU +2 more
openaire +4 more sources
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review
Respiratory Research, 2021 Background The COVID-19 pandemic has affected the world extraordinarily. This disease has a potential to cause a significantly severe course of disease leading to respiratory complications, multiple organ failure and possibly death.
Alina Kröker, Madara Tirzīte
doaj +1 more source
Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [PDF]
, 2020 As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise.
Brown, Cortlyn +2 more
core
Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2 [PDF]
, 2020 Background and purpose Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported.
Boon, Paul +6 more
core +2 more sources
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
European Journal of Medical Research, 2022 The global COVID-19 pandemic has affected the world’s population by causing changes in behavior, such as social distancing, masking, restricting people’s movement, and evaluating existing medication as potential therapies.
Farshad M. Shirazi +5 more
doaj +1 more source
Frontiers in Pharmacology, 2022 COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs. Critically ill patients are easily complicated by cytokine storms, acute respiratory distress syndrome (ARDS), and respiratory failure, which seriously threaten their ...
Hao Shen +14 more
doaj +1 more source
Molecular Oncology, EarlyView.Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee +8 more
wiley +1 more source
Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics
Pharmaceutics, 2021 An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic.
Matteo Puccetti +3 more
doaj +1 more source